Reiterating anticipated DANYELZA net product revenues of between $80 M and $85M; Lowering anticipated operating expenses to between $110M and $115M from previous guidance of between $115 Mand $120M; ed total annual cash burn to between $27 M and $32M rom previous guidance of between $40M and $50M and Cash and cash equivalents now anticipated to support operations as currently planned into 2027 compared to previous cash runway guidance into 2026. l
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on YMAB:
- YMAB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023
- Y-mAbs Therapeutics appoints Michael Rossi as CEO
- Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director
- Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA
